A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3152 in Healthy Japanese Adults
Latest Information Update: 31 Dec 2024
At a glance
- Drugs Sipavibart (Primary) ; Sipavibart (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 27 Dec 2024 Status changed from active, no longer recruiting to completed.
- 05 Jan 2024 Planned End Date changed from 17 Jan 2025 to 19 Dec 2024.
- 05 Jan 2024 Planned primary completion date changed from 17 Jan 2025 to 19 Dec 2024.